ReviewAnnals of surgical oncology2025
Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.
Review in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- Pushing the boundaries of surgical resectability in colorectal liver metastases: the advancing role of two-stage hepatectomy.Hepatobiliary surgery and nutrition · 2026Article
- Seeing the invisible: Three-dimensional liver modeling from simulation to the scalpel.Annals of hepato-biliary-pancreatic surgery · 2026Review
- Improving surgical treatments for hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2026Review
- [Conditioning and systemic treatment before extensive liver resection].Chirurgie (Heidelberg, Germany) · 2026Review
- Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies.Translational gastroenterology and hepatology · 2026Review
- Review
- Clinicopathological insights and management of liver metastases: Current advances and future perspectives.World journal of hepatology · 2025Review
- ASO Author Reflections: Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The optimization of the future liver remnant (FLR) is paramount in improving outcomes for patients undergoing liver surgery, as post-hepatectomy liver failure remains a major source of postoperative morbidity and mortality. A wide collection of techniques has been introduced with the goal of augmenting the FLR prior to hepatectomy for primary and secondary liver malignancies, and these modalities include portal vein embolization (PVE), portal vein ligation (PVL), liver venous deprivation (LVD), associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), and radioembolization (e.g., Y-90). There are advantages and drawbacks for each of these methods regarding the capacity for FLR hypertrophy sufficient for resection, perioperative morbidity/mortality, and long-term oncologic outcomes. In the context of technical variations when performing the procedures, there have been comparative studies between the various methods of FLR optimization, however, not many in a controlled fashion. Results from ongoing and future randomized controlled trials will help refine these techniques, directly compare outcomes, and personalize strategies based on patient-specific factors. In this review, the benefits of the various FLR augmentation approaches are summarized and the current literature and trials are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.